Truist Securities analyst Supawat Thongthip assumes Sutro Biopharma (NASDAQ:STRO) with a Buy rati

Barclays analyst Lukas Shumway initiates coverage on Sutro Biopharma (NASDAQ:STRO) with a Overwei

U.S. stock futures lower with Nasdaq down 200 points. XP Inc (XP) falls after reporting lower-than-e

Agilysys Inc (AGYS) shares rose in pre-market trading after reporting better-than-expected financial

Leerink Partners maintains Sutro Biopharma (NASDAQ:STRO) with a Outperform and raises the price ta

Wedbush analyst David Nierengarten upgrades Sutro Biopharma (NASDAQ:STRO) from Neutral to Outperf

Dow Jones falls 400 points, while Gemini Space Station Inc (NASDAQ: GEMI) sees 25.7% jump after stro

Analysts change outlook on top Wall Street names. Piper Sandler cuts target for Figma to $30, Roth C

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Sutro Biopharma (NASDAQ:STRO) with

Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(2.94) per share which beat the analyst

– On track to report initial safety, PK and early activity from Phase 1 dose-escalation trial of STR

Top analysts change outlook on top names, including upgrades, downgrades, and initiations. Check out

Pre-Market Stock Futures: Futures are trading higher this morning after a messy Wednesday trading se

Mizuho analyst Salim Syed initiates coverage on Sutro Biopharma (NASDAQ:STRO) with a Outperform r

Citizens analyst Reni J. Benjamin maintains Sutro Biopharma (NASDAQ:STRO) with a Market Outperfor

STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid t

Sutro Biopharma, Inc. (NASDAQ: STRO - Get Free Report)'s stock price traded up 10.4% on Friday after

Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume.

Analysts change ratings & price targets for HSCS, ONDS, STRO, PFE, HST, CABA, INSM, PVH. See ful

– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC;

Sutro Biopharma, Inc. (NASDAQ: STRO - Get Free Report) has been given an average recommendation of "

Sutro Biopharma is an early-stage ADC developer, trading at a $406m market cap after a strong 6-mont

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the C

Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume.

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the C

Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume.

Sutro Biopharma, Inc. (STRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Sutro Biopharma, Inc. (NASDAQ: STRO - Get Free Report) has been given a consensus recommendation of

Shares of Sutro Biopharma, Inc. (NASDAQ: STRO - Get Free Report) have received a consensus recommend

Sutro Biopharma, Inc. ( STRO ) Discusses Strategic Reset and Progress in Next-Generation ADC Pipelin

Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.67 per share versus the Zacks Cons

– Company announces U.S. FDA clearance of Investigational New Drug (IND) application for STRO-004, i

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the C

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the C

  During the session on Thursday, 461 stocks hit new 52-week lows.

  During Monday's trading, 1214 companies set new 52-week lows.

  During Thursday, 849 stocks hit new 52-week lows.

    Tuesday's session saw 729 companies set new 52-week lows.

    On Friday, 209 companies set new 52-week lows.